Cite
MLA Citation
Sven de Vos et al.. “Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study.” Leukemia & lymphoma, vol. 62, no. 4, 2021, pp. 810–818. http://access.bl.uk/ark:/81055/vdc_100127473100.0x000032